Company Description
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.
It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products.
The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications.
In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans.
The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa’s Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| Country | United States |
| Founded | 1979 |
| IPO Date | Nov 5, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Mark Emalfarb |
Contact Details
Address: 1044 North U.S. Highway One, Suite 201 Jupiter, Florida 33477-5094 United States | |
| Phone | 561 743 8333 |
| Website | dyadic.com |
Stock Details
| Ticker Symbol | DYAI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001213809 |
| CUSIP Number | 26745T101 |
| ISIN Number | US26745T1016 |
| Employer ID | 45-0486747 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark A. Emalfarb | Founder, Chief Executive Officer, President and Director |
| Ping Wang Rawson CPA, M.B.A. | Chief Financial Officer |
| Joseph P. Hazelton | Chief Operating Officer |
| Ana Gómez Rodriguez | Secretary of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 5, 2025 | 8-K | Current Report |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | 8-K | Current Report |
| Apr 2, 2025 | EFFECT | Notice of Effectiveness |
| Mar 31, 2025 | 144 | Filing |
| Mar 28, 2025 | UPLOAD | Filing |
| Mar 26, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 10-K | Annual Report |